What is the reason Italy's antitrust authority has opened an investigation into Biogen Italia and its parent company?

Italy's antitrust authority has opened an investigation into Biogen Italia and its parent company Biogen (BIIB.O) over alleged abuse of a dominant position, specifically aiming to exclude rival Sandoz (SDZ.S) from offering multiple sclerosis drugs based on the active ingredient natalizumab.

What actions did Italy's antitrust watchdog take as part of this investigation?

The watchdog carried out inspections at Biogen's Italian offices, assisted by Italy's finance police.

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 26, 2026

Italy's antitrust authority opened an investigation into Biogen over allegations of abusing its dominant position to exclude rival Sandoz from the multiple sclerosis drug market.

reuters

2026-05-26

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

2026-07-29

Biogen Beats Quarterly Estimates as Newer Drugs Fuel Growth

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

FAQ